I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment

I-SPY2 platform-based phase II studies in breast cancer might speed up the development of new treatments. In this issue of Cancer Cell, Pusztai et al. report that adding durvalumab and olaparib to standard neoadjuvant chemotherapy significantly increases the pathological complete response rate in patients with HER2-negative breast cancer irrespective of the hormone receptor status.

Automated summary

The phase II studies on breast cancer using the I-SPY2 platform have shown promising results in accelerating the development of new treatments. Adding durvalumab and olaparib to standard neoadjuvant chemotherapy significantly increased the pathological complete response rate in HER2-negative breast cancer patients, regardless of hormone receptor status.